OTTAWA, ONTARIO--(Marketwire- May 13, 2010) - PharmaGap Inc. (TSXVENTURE:GAP)(OTCBB:PHRGF) ("PharmaGap" or "the Company") is pleased toannounce the latest results from testing of its lead drug compoundGAP-107B8 at the National Cancer Institute ("NCI") in Bethesda, MD.These results reflect a second test conducted by NCI to confirm resultsof the same test earlier this year.

Most striking results showed a dose dependent effect of thedrug in causing cancer cell death; Prostate Cancer up to 100%; Melanomaup to 92%; and Colon Cancer up to 86%.

These tests were designed to investigate effect across theNCI's 60 cell human tumour panel at drug dosage levels from 5 to 80micromolars. This test program was conducted twice, beginning in Januarythis year. The results from the first test were made available to theCompany in early March, and the Company was advised by the NCI that thetest would be repeated in order to confirm the results. Results from thefirst test program have been confirmed by the second test for whichresults have now been received. Overall, in 37 of 60 tumour cell lines,across all cancer types tested, at dosage levels of 20 to 40micromolars, 100% growth inhibition and greater than 20% cell death wasobserved. The range of results over the 60 cell lines by cancer type,expressed as growth inhibition (GI) or cell death (CD) percentages, was:

Note: an additional cancer type (6 cell lines) is notreported here in order to preserve the Company's intellectual propertyrights for this cancer type in future filings.

This response profile information generated at the NCI isconsistent with in vitro results generated in prior testing bythe company and serve to confirm these prior results.

The company will now accelerate its program to deliverrequired data to obtain from the US Food and Drug Administration (FDA)Investigative New Drug (IND) approval to begin clinical trials. TheCompany has established a new full time executive position, VicePresident Clinical Development, and is seeking to fill that role with adedicated executive with depth of experience in taking drugs throughclinical trials in the coming weeks. .

Robert McInnis, President and CEO of PharmaGap, stated "Thesevery positive results allow us to adjust the timing and the strategy tothe drive to human trials for this drug. We intend to apply additionalresources and fill the Vice President, Clinical Development position assoon as possible in order to accelerate our program to bring this drugto human trials in as timely a manner as possible and to maximize ourchances of success. As this program advances, we continue to report ourprogress to potential licensing and development partners. We will beproviding a further report shortly on the program to move to IND."

About PharmaGap Inc.

PharmaGap Inc. (TSX VENTURE:GAP)(OTCBB:PHRGF), based inOttawa, ON, is a biotechnology company with a core focus on developingnovel peptide therapeutics for the treatment of cancer. PharmaGap'sGAP-107B8 is a novel peptide drug designed to inhibit the activity ofprotein kinase C (PKC), a cell signalling enzyme implicated in certaintypes and stages of cancer. Independent peer-reviewed research hasdemonstrated that over-expression of PKC plays a role in the developmentof many cancer types. For more information please visit www.pharmagap.com.

Note: Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracy ofthis release. No Securities Commission or other regulatory authorityhaving jurisdiction over PharmaGap has approved or disapproved of theinformation contained herein. This release contains forward lookingstatements that may not occur or may change materially.